2019 CYIR Finalized

12 TREATMENT OF COPD Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK,Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ,Investigators I. Once- Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med . 2018; 378: 1671-1680 Summary In this randomized trial involving 10,355 patients with COPD, 52 weeks of a once-daily combination of flutica- sone furoate (an inhaled glucocorticoid), umeclidinium (a LAMA), and vilanterol (a LABA) [triple therapy] was com- pared with fluticasone furoate-vilanterol (ICS/LABA) and umeclidinium-vilanterol (LAMA/LABA). Each regimen was administered in a single Ellipta inhaler. The rate of mod- erate or severe exacerbations in the triple-therapy group was 0.91 per year, as compared with 1.07 per year in the ICS/LABA group (rate ratio with triple therapy, 0.85; 95% confidence interval [CI], 0.80 to 0.90; 15% difference; P<0.001) and 1.21 per year in the LAMA/LABA group (rate ratio with triple therapy, 0.75; 95% CI, 0.70 to 0.81; 25% difference; P<0.001). The annual rate of severe exacerba- tions resulting in hospitalization in the triple-therapy group was 0.13, as compared with 0.19 in the LAMA/LABA group (rate ratio, 0.66; 95% CI, 0.56 to 0.78; 34% difference; P<0.001). There was a higher incidence of pneumonia in the inhaled-glucocorticoid groups than in the LAMA/LABA group, and the risk of clinician-diagnosed pneumonia was significantly higher with triple therapy than with LAMA/ LABA, as assessed in a time-to-first-event analysis (hazard ratio, 1.53; 95% CI, 1.22 to 1.92; P<0.001). Triple therapy resulted in a lower rate of moderate or severe COPD exac- erbations than ICS/LABA or LAMA/LABA in this popula- tion. Triple therapy also resulted in a lower rate of hospital- ization due to COPD than LAMA/LABA. Comments 1. Once-daily single-inhaler triple therapy (ICS/LABA/LAMA) resulted in a significantly lower rate of moderate or severe COPD exacerbations and better lung function and health- related quality of life than dual therapy with fluticasone furoate– vilanterol or the dual bronchodilator umeclidinium–vilanterol among patients with symptomatic COPD and a history of exacerbations. 2. The finding that ICS/LABA was superior to LAMA/LABA with respect to the rates of COPD exacerbations is in contrast to those of the FLAME trial. 3. The strengths of the IMPACT trial include the large number of patients enrolled and the comparison of triple therapy with dual therapies using the same molecules in the same delivery device. 4. Subjects in the IMPACT trial who were assigned to the LAMA– LABA group and had been previously receiving an ICS would have had to abruptly stop the ICS, thus it is unknown whether the abrupt discontinuation of ICS could have contributed to the finding of a lower rate of exacerbations in the ICS groups than in the LAMA–LABA group. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S,Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy ver- sus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076-1084. Summary This study compared a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrro- nium (IND/GLY) in terms of the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment. This randomised, parallel-group, double-blind, double-dummy study was done at 187 sites across 17 countries. Eligible patients had symptomatic COPD, severe or very severe airflow limitation, at least one moderate or severe exac- erbation in the previous year and were receiving inhaled maintenance medication. After a 2 week run-in period with one inhalation per day of IND/GLY, patients were randomly assigned (1:1), to receive 52 weeks of treatment with two inhalations of extrafine BDP/FF/G twice per day or one inhalation of IND/GLY per day. 1532 patients received BDP/FF/G (n=764) or IND/GLY (n=768). Moderate-to- severe exacerbation rates were 0·50 per patient per year (95% CI 0·45-0·57) for BDP/FF/G and 0·59 per patient per year (0·53-0·67) for IND/GLY, giving a rate ratio of 0·848 (0·723-0·995, p=0·043) in favor of BDP/FF/G. In patients with symptomatic COPD, severe or very severe airflow lim- itation, and an exacerbation history despite maintenance therapy, extrafine BDP/FF/G significantly reduced the rate of moderate-to-severe exacerbations compared with IND/ GLY, without increasing the risk of pneumonia. SUNDAY, MAY 19 COPD Nadia N. Hansel, MD, MPH Johns Hopkins University Department of Medicine Baltimore, MD COPD

RkJQdWJsaXNoZXIy MTM1ODMw